```html

Myeloma: A Complete Patient Guide

Overview

Multiple myeloma is a cancer of plasma cells, a type of white blood cell that lives in the bone marrow and produces antibodies. When these cells become malignant, they multiply uncontrollably, crowd out normal blood‑forming cells, and secrete abnormal proteins that damage bone, kidney, and immune function.

Who it affects: Myeloma most commonly occurs in adults over 65 years of age, and it is about twice as frequent in men as in women. In the United States, there were an estimated 34,000 new cases and 12,000 deaths in 2023, representing roughly 1% of all cancers worldwide (WHO).

Although myeloma is considered a “rare” cancer, advances in therapy have shifted the disease from a rapidly fatal condition to a chronic, treatable illness for many patients.

Symptoms

Symptoms develop slowly and can be mistaken for aging or other medical problems. Below is a comprehensive list with brief explanations.

• Bone pain: Usually in the back, ribs, hips, or skull. Pain may be constant or worsen with movement.
• Pathologic fractures: Bones weakened by myeloma can break with minimal trauma.
• Fatigue and weakness: Result from anemia (low red blood cells) and the body’s effort to fight infection.
• Recurrent infections: Abnormal plasma cells produce ineffective antibodies, reducing immunity.
• Hypercalcemia (high blood calcium): Bone breakdown releases calcium, causing nausea, constipation, increased thirst, confusion, or kidney stones.
• Kidney problems: The abnormal protein (M‑protein) can clog renal tubules, leading to decreased urine output or swelling (edema).
• Unexplained weight loss: May accompany chronic disease.
• Numbness or tingling: Nerve compression from bone lesions in the spine can cause peripheral neuropathy.
• Blood abnormalities: Low platelets (thrombocytopenia) leading to easy bruising or prolonged bleeding.
• Elevated ESR or CRP: General markers of inflammation that are often high in myeloma.

Causes and Risk Factors

The exact cause of multiple myeloma is unknown, but research points to a combination of genetic, environmental, and lifestyle influences.

Genetic factors

• Family history of myeloma or related plasma‑cell disorders (e.g., MGUS – monoclonal gammopathy of undetermined significance).
• Specific chromosomal abnormalities such as translocation t(4;14), t(14;16), or deletion of 17p13 (TP53) are associated with higher risk and poorer prognosis (Cleveland Clinic).

Environmental and occupational exposures

• Exposure to ionizing radiation (e.g., atomic‑bomb survivors, therapeutic radiation).
• Contact with certain chemicals, such as benzene, pesticides, or petroleum products.

Other risk factors

• Age > 65 years.
• Male sex.
• African‑American heritage: incidence is about 2–3 times higher than in Caucasians (NIH).
• Obesity: Higher body‑mass index has been linked to increased risk.
• Chronic immune stimulation (e.g., long‑standing autoimmune disease).

Diagnosis

Diagnosing myeloma involves a combination of blood tests, urine studies, imaging, and bone‑marrow evaluation. No single test is definitive.

Laboratory tests

• Complete blood count (CBC): May reveal anemia, low platelets, or leukopenia.
• Serum protein electrophoresis (SPEP) & immunofixation: Detects the M‑protein (monoclonal spike).
• Serum free light‑chain assay: Measures κ and λ light chains; an abnormal ratio supports diagnosis.
• β2‑microglobulin and albumin levels: Used for staging (International Staging System).
• Renal function tests (creatinine, BUN): Assess kidney involvement.
• Calcium level: Hypercalcemia is a common presenting feature.

Urine tests

• 24‑hour urine protein electrophoresis (UPEP): Detects Bence‑Jones protein (free light chains) excreted in urine.

Imaging studies

• Whole‑body low‑dose CT or PET/CT: Identifies lytic bone lesions and extramedullary disease.
• Magnetic resonance imaging (MRI): Highly sensitive for detecting spinal involvement and soft‑tissue plasmacytomas.
• Bone survey (skeletal X‑rays): Traditional method but less sensitive than modern cross‑sectional imaging.

Bone‑marrow biopsy

A definitive diagnosis requires a bone‑marrow aspirate/biopsy showing ≥10% clonal plasma cells or a biopsy of a plasmacytoma. Cytogenetic analysis (FISH) and next‑generation sequencing help risk‑stratify the disease.

Treatment Options

Treatment is individualized based on disease stage, patient age, kidney function, and genetic risk. Goals are to control the tumor, preserve organ function, and maintain quality of life.

First‑line (induction) therapy

• Triplet regimens:
  • VRd – Bortezomib (proteasome inhibitor) + Lenalidomide (IMiD) + Dexamethasone.
  • KRd – Carfilzomib + Lenalidomide + Dexamethasone.
  • Dara‑VRd – Daratumumab (anti‑CD38 monoclonal antibody) added to VRd.
• These combinations achieve deep responses in 60–80% of patients (Mayo Clinic).

High‑dose therapy & stem‑cell transplant

For eligible patients (generally <70 y, good organ function), high‑dose melphalan followed by autologous stem‑cell transplantation (ASCT) prolongs progression‑free survival (PFS) by 2–3 years.

Maintenance therapy

• Lenalidomide is the most common maintenance drug, taken daily/weekly for years, reducing relapse risk.
• In patients with high‑risk cytogenetics, proteasome inhibitor maintenance (e.g., ixazomib) may be added.

Relapsed/refractory options

• Pomalidomide + Dexamethasone (with or without daratumumab).
• CAR‑T cell therapy: Ide‑cabtagene vicleucel (ide‑cab) approved in 2021 for patients who have received ≥3 prior lines.
• Bispecific antibodies: Teclistamab (BCMA‑CD3) shows promising response rates.
• Clinical trial enrollment is encouraged whenever possible.

Supportive care & lifestyle measures

• Bisphosphonates (e.g., zoledronic acid) or denosumab to prevent skeletal events.
• Growth‑factor support (e.g., G‑CSF) for neutropenia.
• Vaccinations (influenza, pneumococcal, COVID‑19) to reduce infection risk.
• Renal‑protective measures: adequate hydration, avoid nephrotoxic drugs (NSAIDs, contrast).
• Physical therapy and weight‑bearing exercise to strengthen bone and improve stamina.

Living with Myeloma

Myeloma is now managed as a chronic disease; daily habits can influence outcomes and quality of life.

Medication adherence

• Set alarms or use pill‑organizers.
• Report side‑effects promptly—dose adjustments often prevent discontinuation.

Nutrition

• High‑protein, low‑sodium diet to support bone health and kidney function.
• Limit calcium‑rich supplements if hypercalcemia is present; discuss with your doctor.
• Stay hydrated (2–3 L/day) unless fluid restriction is ordered.

Exercise

• Low‑impact activities—walking, swimming, stationary cycling—most days for 30 minutes.
• Strength training (under supervision) 2–3 times weekly to maintain muscle mass.
• Balance exercises reduce fall risk, especially if bone lesions exist.

Emotional well‑being

• Join support groups (e.g., International Myeloma Foundation). Sharing experiences reduces isolation.
• Consider counseling or mindfulness programs to manage anxiety and depression.

Regular monitoring

• Every 2–3 months: blood work (CBC, calcium, creatinine, M‑protein), physical exam.
• Imaging every 6–12 months or sooner if new pain develops.

Prevention

Because myeloma’s root cause is not fully understood, specific primary‑prevention strategies are limited. However, general cancer‑prevention measures may lower risk:

• Avoid known carcinogens: Minimize exposure to benzene, pesticides, and unnecessary radiation.
• Maintain a healthy weight: Obesity is linked to higher myeloma incidence.
• Stay physically active: Regular exercise may reduce inflammatory pathways.
• Balanced diet: Plenty of fruits, vegetables, whole grains, and limited processed meats.
• Regular medical check‑ups: Early detection of MGUS (a benign precursor) allows close surveillance.

Complications

If left untreated or poorly controlled, myeloma can lead to serious complications:

• Pathologic fractures – often require surgery and prolonged immobilization.
• Renal failure – due to light‑chain deposition; can become irreversible.
• Severe infections – opportunistic pathogens (e.g., Pneumocystis, herpes zoster) may be life‑threatening.
• Hyperviscosity syndrome – thickened blood from high M‑protein causing visual changes, headache, or neurological deficits.
• Spinal cord compression – from vertebral lesions; requires urgent decompression.
• Secondary cancers – long‑term immunosuppression and certain drugs increase risk of therapy‑related AML or solid tumors.

When to Seek Emergency Care

---

References: Mayo Clinic, CDC, NIH, WHO, Cleveland Clinic, International Myeloma Foundation, peer‑reviewed journals (Blood, J Clin Oncol, Lancet Haematology). All links accessed May 2026.

```